Helixmith Plunges On Warning Of Possible Offering Delay

Investment Losses Also Concern Shareholders

Korean venture Helixmith faces another setback following a missed Phase III endpoint for its plasmid DNA neuropathy candidate, with its shares plunging after it warned of a possible delay in a planned rights offering, amid concerns from minority shareholders over other investment losses.

Delayed Offering Could Place Helixmith Shares Under Market Supervision • Source: Shutterstock

Helixmith Co., Ltd. shares have fallen sharply on concerns over its financial standing as it reported hefty investment losses and a possible delay in a planned rights offering this year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Helixmith Plunges On Warning Of Possible Offering Delay

Investment Losses Also Concern Shareholders

Read the full article – start your free trial today!

More from South Korea

More from Focus On Asia